WEKO3
アイテム
{"_buckets": {"deposit": "2557a464-d84f-408d-901b-788fbfb3b1c6"}, "_deposit": {"created_by": 1, "id": "71474", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "71474"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00071474", "sets": ["28"]}, "author_link": ["702792", "702785", "702784", "702789", "702787", "702790", "702782", "702783", "702794", "702795", "702791", "702788", "702793", "702786"], "item_10005_date_7": {"attribute_name": "発表年月日", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2014-06-09", "subitem_date_issued_type": "Issued"}]}, "item_10005_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Objectives: The aim of the present study was to evaluate the clinical value of PET/CT with FAZA, a PET probe for tumor hypoxia, for advanced lung cancer patients, in comparison to FDG-PET/CT.\n\\nMethods: Thirty four patients with non-small cell lung cancer (stage III and IV) received PET/CT with FAZA and FDG. After treatment, patients were followed to evaluate the treatment response and survival. Overall-, progression-free survival, local control and control of LN metastases were compared with uptake parameters of FAZA (tumor-muscle ratio at 2h (T/M)) and FDG (SUVmax at 1h (SUV)). Study protocol was approved by the institutional review board, and informed consent was obtained from all patients.\n\\nResults: There was a weak correlation between FAZA T/M and FDG SUV of primary lesion, but intra-tumoral distribution patterns were not identical. Stage IV patients tended to show worse overall- and progression-free survival than stage III patients (p=0.122 and 0.124, respectively). Although not statistically significant, mean FAZA T/M of primary lesion tended to be higher in non-survivors and in patients with disease progression, whereas such tendency was not observed for mean FDG SUV. Furthermore, patients with FAZA T/M \u003e 2.245 showed significantly worse progression-free survival (p=0.028). Patients who developed local recurrence showed significantly higher mean FAZA T/M (p=0.009) of primary lesion than who did not. In contrast, significantly higher mean FDG SUV of LN metastasis was observed in patients who developed recurrence in LN metastasis (p = 0.043). Mean FAZA T/M of LN metastasis was also higher in patients who developed LN recurrence (p = 0.070). \n\\nConclusion: PET/CT with FAZA may have a potential for the prediction of disease control and survival of advanced lung cancer patients.", "subitem_description_type": "Abstract"}]}, "item_10005_description_6": {"attribute_name": "会議概要(会議名, 開催地, 会期, 主催者等)", "attribute_value_mlt": [{"subitem_description": "SNMMI 2014 Annual meeting ", "subitem_description_type": "Other"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Saga, Tsuneo"}], "nameIdentifiers": [{"nameIdentifier": "702782", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Inubushi, Masayuki"}], "nameIdentifiers": [{"nameIdentifier": "702783", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Koizumi, Mitsuru"}], "nameIdentifiers": [{"nameIdentifier": "702784", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshikawa, Kyosan"}], "nameIdentifiers": [{"nameIdentifier": "702785", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhang, Ming-Rong"}], "nameIdentifiers": [{"nameIdentifier": "702786", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Horiike, Atsushi"}], "nameIdentifiers": [{"nameIdentifier": "702787", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kudo, Keita"}], "nameIdentifiers": [{"nameIdentifier": "702788", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ohyanagi, Fumiyoshi"}], "nameIdentifiers": [{"nameIdentifier": "702789", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nishio, Makoto"}], "nameIdentifiers": [{"nameIdentifier": "702790", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "佐賀 恒夫", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "702791", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "犬伏 正幸", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "702792", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "小泉 満", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "702793", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "吉川 京燦", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "702794", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "張 明栄", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "702795", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "conference object", "resourceuri": "http://purl.org/coar/resource_type/c_c94f"}]}, "item_title": "Clinical evaluation of FAZA and FDG PET/CT for advanced lung cancer patients.", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Clinical evaluation of FAZA and FDG PET/CT for advanced lung cancer patients."}]}, "item_type_id": "10005", "owner": "1", "path": ["28"], "permalink_uri": "https://repo.qst.go.jp/records/71474", "pubdate": {"attribute_name": "公開日", "attribute_value": "2014-06-20"}, "publish_date": "2014-06-20", "publish_status": "0", "recid": "71474", "relation": {}, "relation_version_is_last": true, "title": ["Clinical evaluation of FAZA and FDG PET/CT for advanced lung cancer patients."], "weko_shared_id": -1}
Clinical evaluation of FAZA and FDG PET/CT for advanced lung cancer patients.
https://repo.qst.go.jp/records/71474
https://repo.qst.go.jp/records/71474eadb3239-cbb2-4dbe-ab9b-1b5f085f1254
Item type | 会議発表用資料 / Presentation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2014-06-20 | |||||
タイトル | ||||||
タイトル | Clinical evaluation of FAZA and FDG PET/CT for advanced lung cancer patients. | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
資源タイプ | conference object | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Saga, Tsuneo
× Saga, Tsuneo× Inubushi, Masayuki× Koizumi, Mitsuru× Yoshikawa, Kyosan× Zhang, Ming-Rong× Horiike, Atsushi× Kudo, Keita× Ohyanagi, Fumiyoshi× Nishio, Makoto× 佐賀 恒夫× 犬伏 正幸× 小泉 満× 吉川 京燦× 張 明栄 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Objectives: The aim of the present study was to evaluate the clinical value of PET/CT with FAZA, a PET probe for tumor hypoxia, for advanced lung cancer patients, in comparison to FDG-PET/CT. \nMethods: Thirty four patients with non-small cell lung cancer (stage III and IV) received PET/CT with FAZA and FDG. After treatment, patients were followed to evaluate the treatment response and survival. Overall-, progression-free survival, local control and control of LN metastases were compared with uptake parameters of FAZA (tumor-muscle ratio at 2h (T/M)) and FDG (SUVmax at 1h (SUV)). Study protocol was approved by the institutional review board, and informed consent was obtained from all patients. \nResults: There was a weak correlation between FAZA T/M and FDG SUV of primary lesion, but intra-tumoral distribution patterns were not identical. Stage IV patients tended to show worse overall- and progression-free survival than stage III patients (p=0.122 and 0.124, respectively). Although not statistically significant, mean FAZA T/M of primary lesion tended to be higher in non-survivors and in patients with disease progression, whereas such tendency was not observed for mean FDG SUV. Furthermore, patients with FAZA T/M > 2.245 showed significantly worse progression-free survival (p=0.028). Patients who developed local recurrence showed significantly higher mean FAZA T/M (p=0.009) of primary lesion than who did not. In contrast, significantly higher mean FDG SUV of LN metastasis was observed in patients who developed recurrence in LN metastasis (p = 0.043). Mean FAZA T/M of LN metastasis was also higher in patients who developed LN recurrence (p = 0.070). \nConclusion: PET/CT with FAZA may have a potential for the prediction of disease control and survival of advanced lung cancer patients. |
|||||
会議概要(会議名, 開催地, 会期, 主催者等) | ||||||
内容記述タイプ | Other | |||||
内容記述 | SNMMI 2014 Annual meeting | |||||
発表年月日 | ||||||
日付 | 2014-06-09 | |||||
日付タイプ | Issued |